Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

Larry K Kvols, Kjell E Oberg1, Thomas M O'Dorisio2, Pharis Mohideen3, Wouter W de Herder4, Rudolf Arnold5, Ke Hu3, Yilong Zhang3, Gareth Hughes6, Lowell Anthony7 and Bertram Wiedenmann8

H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
1Department of Endocrine Oncology, University Hospital, Uppsala, Sweden
2Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA
3Novartis Pharmaceuticals, East Hanover, New Jersey, USA
4Erasmus Medical Center, Rotterdam, The Netherlands
5Philipps-Universität, Marburg, Germany
6Novartis Pharma AG, Basel, Switzerland
7Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
8Universitätsklinikum Charité, Virchow-Klinikum, Berlin, Germany

(Correspondence should be addressed to L K Kvols; Email: larry.kvols@moffitt.org)

Abstract

Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and sst5. Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150 mg twice daily (bid), escalated to a maximum dose of 1200 mg bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600–900 mg s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600–900 mg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.

Endocrine-Related Cancer (2012) 19 657–666

Introduction

Neuroendocrine tumors (NETs) are often asymptomatic and by the time of diagnosis have frequently metastasized, usually to the liver (Modlin et al. 2005). The majority of NETs are gastrointestinal (historically referred to as carcinoid tumors) and are characterized by hypersecretion of biogenic amines, peptides, and polypeptides, such as serotonin, tachykinins, and chromogranin A (CgA; Long et al. 1981, Fajans & Vinik 1989, Modlin et al. 2005). The excessive release
of these amines and peptide hormones, especially serotonin and substance P, is responsible for the principal symptoms of diarrhea and flushing associated with carcinoid syndrome.

Surgery is essential in the management of metastatic NETs and can be curative for early disease (Loftus & van Heerden 1995, Plockinger et al. 2004). However, the majority of patients require medical treatment either as an adjuvant to surgery, particularly when total resection is not possible, or as first-line treatment in patients not indicated for surgery.

The somatostatin (sst) analogs octreotide and lanreotide have been the mainstay for symptom management in patients with NETs. Octreotide and lanreotide have a high affinity for the sst receptor subtype 2 (sst2) and a modest affinity for sst5 (Bruns et al. 1994). However, expression of multiple sst subtypes is observed in NETs (Hofland & Lamberts 2003). Although octreotide LAR therapy effectively reduces the symptoms of carcinoid syndrome in the majority of patients (Rubin et al. 1999, Modlin et al. 2006), a considerable number of patients will experience an escape from response within months to several years of treatment, whereupon symptoms may return, and the prognosis for these patients is poor (Hofland et al. 2005). Mechanisms by which this desensitization to currently available sst analogs may occur include sst2 internalization and downregulation on tumor cells, over-expression of other sst receptor subtypes (Ronga et al. 1995, Li et al. 2004, Schmid & Schoeffter 2004), or other unknown mechanisms. Targeting multiple ssts in NETs may provide an effective treatment for the relief of symptoms in patients who are no longer responsive to the currently available sst analogs.

Pasireotide (SOM230) is a novel multireceptor-targeted sst analog with high binding affinity to four of the five known sst receptor subtypes (sst1,2,3 and sst5; Bruns et al. 2002, Boerlin et al. 2003, Schmid & Schoeffter 2004). Compared with octreotide, pasireotide has 30-, 5-, and 39-fold higher affinity for sst1,3 and sst5, respectively, and a slightly lower affinity for sst2 (Bruns et al. 2002, Boerlin et al. 2003, Schmid & Schoeffter 2004). Because of this receptor binding profile, pasireotide may offer symptom reduction in patients who are inadequately controlled with octreotide LAR therapy. This paper presents results from a phase II, open-label, multicenter study designed to assess the efficacy and safety of pasireotide in patients with advanced NETs whose symptoms were refractory or resistant to octreotide LAR therapy.

Materials and methods

Study population

Eligible patients were required to be aged ≥ 18 years with histopathologically and biochemically confirmed metastatic NETs of the digestive system of any grade with or without disease progression. Patients had elevated urinary 5-hydroxyindole acetic acid (5-HIAA) and/or serum CgA levels, one or more measurable lesions (excluding bone) that demonstrated progression since radiation or had not been previously irradiated, and a Karnofsky performance status ≥60. Inadequate control of disease was defined as a mean of ≥ 4 bowel movements per day or a mean of ≥ 2 episodes of flushing per day for at least 2 weeks during the 28-day period following the last dose of octreotide LAR (screening/baseline period). Patients then underwent a 28-day washout period during which time treatment with protocol-approved medication, including octreotide s.c. or over-the-counter medication to control the symptoms of carcinoid syndrome, was permitted up to 48 h before initial administration of pasireotide (Fig. 1).

Key exclusion criteria included patients with uncontrolled diabetes mellitus, malabsorption

![Figure 1](https://www.endocrinology-journals.org)
syndrome, short bowel or chologenic diarrhea not controlled by medication, surgery for loco-regional metastasis within 3 months, or any other major surgery within 1 month of study entry. Patients who had received radiolabeled sst analog therapy within 6 months before receiving pasireotide, and those who had cytotoxic chemotherapy, interferon therapy, or cryoablation of hepatic metastases within 2 months of study entry, were excluded, and patients who had undergone hepatic artery embolization were excluded if treatment was within 6 months, or 1 month if there were other sites of measurable disease. The required time since last dose for long-acting sst analogs, octreotide s.c., and radiolabeled sst analogs was 8 weeks, 2 days, and 6 months respectively.

Study design

This was a phase II, open-label, multicenter, and prospective study (Fig. 1). Enrolled patients self-administered pasireotide 150 μg s.c. twice daily (bid) for a 3-day test period and were assessed for achievement of partial or complete symptom control. Partial symptom control was defined as an average of <4 bowel movements/day, with ≤6 bowel movements on any given day, and an average of <2 episodes of flushing/day over the time interval being studied. Complete symptom control was defined as an average of ≤3 bowel movements/day for at least three consecutive days, with ≤3 episodes on any given day, and no flushing episodes during the time interval being studied. If at least partial symptom control was not achieved within 3 days, the pasireotide dose was escalated by 150 μg/dose up to a limit of 900 μg/dose (1800 μg daily) until partial symptom control over 3 days was achieved. Dose increases up to 1200 μg bid were also approved for some patients based on evidence of therapeutic benefit. If unacceptable toxicity (Common Toxicity Criteria (CTC) grade 3 or higher) occurred, a dose reduction of 150 μg bid to a minimum of 150 μg was permitted. Patients must have received treatment for ≥3 days at any dose before further escalations were allowed.

During the study, the use of prescription medication for diarrhea was prohibited, but exceptions could have been made if the medication was required to treat an adverse event (AE). The use of dexamethasone and octreotide s.c. or other short- or long-acting sst analogs was not permitted. Patients were discouraged from taking over-the-counter medications for diarrhea. If possible, there were to be no changes in any concomitant medications. Additional treatments such as surgery or radiotherapy were prohibited. Any patients requiring these interventions were discontinued from the study before undergoing further treatment.

This study was conducted in accordance with the Declaration of Helsinki. An independent Ethics Committee or Institutional Review Board for each site approved the study protocol. All patients provided written informed consent.

Assessments

The primary efficacy outcome was symptom control (diarrhea and flushing) over any consecutive 15-day period at a fixed dose of pasireotide, assessed using a symptom diary completed daily by the patient. A physician’s assessment of the patient’s symptoms was performed at each scheduled visit. Patients completed the study after undergoing ≥15 consecutive days with at least partial control of symptoms on a fixed dose of pasireotide but could continue to receive pasireotide as long as control was maintained and no unacceptable toxicity or evidence of disease progression was experienced. Patients who reached a dose of 900 μg s.c. bid without achieving at least a partial response over a 15-day period, or were discontinued because of unacceptable drug- or disease-related AEs, were also considered to have completed the study. Pasireotide was considered effective if 30% of patients experienced at least partial symptom control on a constant dose for 15 consecutive days.

Patients were also classified as experiencing complete treatment success (responders), partial treatment success (partial responders), or treatment failure (nonresponders). Complete treatment success was defined as achieving complete symptom control based on 15 consecutive days of treatment at a constant dose level, no more than a 10% increase in biochemical parameters (serum CgA and urinary 5-HIAA) above baseline, and no clinical signs of disease progression as judged by the investigator. Partial treatment success was defined as achieving partial symptom control based on 15 consecutive days of treatment at a constant dose level, but without reaching complete symptom control over the same time period, no more than a 10% increase in biochemical parameters above baseline, and no significant clinical signs of disease progression, as judged by the investigator. Failure to obtain partial or complete treatment success over any consecutive 15-day period at a constant dose level was defined as treatment failure.

The secondary objective of health-related quality of life (HRQoL) was evaluated using the Functional Assessment of Chronic Illness Therapy–Diarrhea (FACIT-D), version 4. FACIT-D comprises the
Functional Assessment of Cancer Therapy–General (FACT-G) score, which measures physical, social, emotional, and functional well-being, supplemented with a symptom-specific subscale, which measures HRQoL specific to diarrhea. All subscales were scored on a Likert scale (0–4) with higher scores indicating a better HRQoL. FACIT-D scores were obtained at baseline (day 1 immediately before pasireotide dosing) and monthly thereafter.

Tumor measurements were made using computed tomography (CT) scans or magnetic resonance imaging (MRI) at baseline and every 3 months thereafter and were assessed using RECIST version 1.0 (Therasse et al. 2000). The same method of tumor assessment used at baseline remained consistent throughout the study. Conventional CT and MRI were performed with cuts of 10 mm or less in slice thickness contiguously. Spiral CT was performed using a 5–8 mm contiguous reconstruction algorithm. The chest, abdomen, and pelvis were scanned. CT or MR images were read by the same radiologist at each assessment, accounting for all lesions that were present at baseline. All known diseases have been accounted for when assessing objective tumor status. Serum CgA and urinary 5-HIAA were obtained at baseline and monthly thereafter. Samples were assessed in a central laboratory.

Following 4 weeks of treatment with pasireotide, plasma samples were collected for pharmacokinetic (PK) analysis. These were collected pre-pasireotide dose and 0.5, 1, 2, 3, 4, and 6 h following the morning dose of pasireotide. The PK parameters minimum plasma concentration after a single dose ($C_{\text{min}}$), maximum plasma concentration after a single dose ($C_{\text{max}}$), time to reach the maximum concentration after a single dose ($t_{\text{max}}$), and area under the plasma concentration–time curve from 0 to 6 h (AUC$_{0-6\,\text{h}}$) were assessed.

Safety and tolerability assessments consisted of reporting all AEs and serious AEs (SAEs), with severity graded according to CTC (grades 1–4). Safety and tolerability assessments were completed at screening, baseline, and monthly thereafter until study completion. Safety assessments included regular monitoring of hematology, blood chemistry, vital signs, physical condition, electrocardiogram readings, and body weight.

Statistical analysis

The total planned sample size was a minimum of 36 patients. The sample size was chosen based on the assumption of a proportion of success of 0.3 and an approximate width of 0.3 for a two-sided 95% confidence interval.

Summary statistics were provided for the primary and secondary endpoints. No formal statistical comparisons were performed for this study.

Results

Between January 2004 and August 2005, a total of 53 patients from nine centers in five countries were enrolled in the study, of whom 45 received pasireotide and were included in the safety analysis and 44 were evaluable for efficacy (Table 1). Of the 45 patients who received treatment, 36 had primary tumors of the small intestine; three had a primary tumor located in the colon, peritoneum, or lung; and five had primary tumors of unknown origin. Most patients (63.6%) had stage IV cancer at baseline. Additionally, the majority of patients (68.2%) were diagnosed R3 years before enrollment into the study. At baseline, 87% of patients had liver metastases. Patients also presented with metastasis to the following locations: lymph node ($n = 16$ patients), peritoneum ($n = 8$), lung ($n = 5$), bone ($n = 3$), abdomen ($n = 3$), pleura ($n = 3$), retroperitoneal ($n = 2$), pancreas ($n = 2$), kidney ($n = 1$), adrenal ($n = 1$), spleen ($n = 1$), and other ($n = 3$).
Of the 45 patients who received pasireotide treatment, 17 completed the study and an additional seven continued receiving pasireotide therapy after completing the study. Discontinuation because of AEs (11 patients) was the most frequent reason for withdrawal. Eight patients withdrew their consent and new cancer therapy was prescribed for two patients. One patient was excluded from the efficacy analyzable population because no post-baseline efficacy assessments were completed. The most frequently reported concomitant medications included proton pump inhibitors (37.8%), natural opium alkaloids (28.8%), antipropulsives (33.3%), and enzyme preparations (31.1%).

Symptom control with pasireotide

Of the 44 patients included in the efficacy analyzable population, 12 (27%) had complete or partial symptom control over 15 days of treatment with pasireotide. Three (7%) of these patients achieved complete control of symptoms (two of whom received pasireotide 600 µg bid and one received 900 µg bid) and nine (20%) achieved partial symptom control in response to treatment (three patients each received pasireotide 600, 750, or 900 µg bid). For the 12 patients who showed complete or partial treatment response, the mean (±S.D.) number of daily bowel movements was reduced from 4.3 ± 1.4 at baseline to 2.8 ± 0.8 post-pasireotide treatment, and mean (±S.D.) daily flushing episodes declined from 4.9 ± 4.1 at baseline to 1.0 ± 0.8 post-treatment (Fig. 2). The mean duration of complete and partial symptom control was 43.7 (range 26–58) days and 72.0 (range 15–244) days respectively. The median treatment duration was 91 (range 1–595) days.

When assessing the number of patients with complete treatment success, partial treatment success, and treatment failure, one (2.3%) patient achieved complete treatment success and four (9.1%) patients achieved partial treatment success. The remaining 39 (88.6%) patients were classified as treatment failures.

Tumor response

Overall tumor response based on RECIST following treatment with pasireotide was assessed in 24 of the 44 patients. At the last assessment before study exit, 57% (13/23) of patients had stable disease, 43% (10/23) of patients had progressive disease, and one patient (4%) had an unknown response. There were no complete or partial tumor responses observed.

Health-related quality of life

Of the 45 patients who received treatment, 30 were included in the HRQoL analysis. In the clinical responder group, more patients had mean HRQoL scores for functional and physical well-being, symptom-specific scores, and FACIT-D summary scores that were slightly higher or the same scores at the end of treatment than at baseline, suggesting an improvement in HRQoL. In the nonresponder group, similar numbers of patients recorded an improvement or a worsening in HRQoL (Table 2).

Biochemical marker data

Median percentage changes in 5-HIAA and CgA levels from baseline in patients with evaluable data are depicted in Fig. 3. Levels of both markers decreased rapidly after pasireotide initiation and remained low.

| Table 2 Mean physical well-being score over time in responders, nonresponders, and patients who discontinued before 3 months of therapy with pasireotide |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Responders by month 3                            | Baseline | Month 1 | Month 2 | Month 3 |
| n                                               | 12      | 12      | 10      | 11      |
| Mean score (S.D.)                               | 21.1 (3.7) | 21.4 (6.3) | 20.0 (4.5) | 21.3 (3.5) |
| Range                                           | 15.8–27.0 | 8.0–28.0 | 11.2–26.0 | 16.0–26.0 |
| Nonresponders by month 3                        | Baseline | Month 1 | Month 2 | Month 3 |
| n                                               | 13      | 13      | 13      | 13      |
| Mean score (S.D.)                               | 21.0 (3.1) | 21.4 (4.5) | 21.1 (4.6) | 22.3 (3.7) |
| Range                                           | 16.0–26.0 | 11.0–27.0 | 13.0–27.0 | 17.0–27.0 |
| Patients who discontinued before 3 months of therapy | Baseline | Month 1 | Month 2 | Month 3 |
| n                                               | 19      | 15      | 8       | –       |
| Mean score (S.D.)                               | 18.0 (5.5) | 17.8 (6.1) | 15.8 (5.8) | –       |
| Range                                           | 9.0–27.0 | 5.0–27.0 | 5.0–24.0 | –       |
Pharmacokinetics

Thirty-five of the 37 patients with available PK plasma samples were analyzed; one patient was excluded because of early discontinuation from the study and one patient was excluded because of missing pre-dose plasma PK samples. The plasma concentration vs time profiles are shown in Fig. 4 and the PK parameters of $C_{\text{min}}$, $C_{\text{max}}$, $t_{\text{max}}$, and AUC$_{0-6}$ h for pasireotide are reported in Table 3. Exposure to pasireotide appeared to increase dose proportionally with pasireotide treatment from 150 to 1200 µg bid, as determined by the mean values for $C_{\text{max}}$, $C_{\text{min}}$, and AUC$_{0-6}$ h (Table 3).

Safety and tolerability

Forty-four of the 45 patients (98%) included in the safety population experienced one or more AE, with 36 patients (80%) considered to have study drug-related AEs (Table 4). The most common AEs with a suspected study drug relationship were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity (CTC grades 1 (36%) and 2 (24%)). Fourteen patients (31%) experienced SAEs; however, only one of these events was suspected to be study drug related; this patient had a CTC grade 4 increase in lipase, which resolved spontaneously and no action was taken. One patient died during the study because of tumor progression that was not considered study drug related. AEs that led to patient discontinuations were general physical health deterioration (grade 3, suspected drug relationship), nausea (grade 3, suspected drug relationship), tumor progression (grade 4, unrelated to study drug), diarrhea (grade 3, unrelated to study drug), abdominal pain (grade 3, suspected drug relationship), bone pain due to metastasis (grade 4, unrelated to study drug), abdominal cramping and bloating (each grade 2, both suspected drug relationship), tumor metastasis (grade 3, unrelated to study drug), worsening diarrhea (grade 2, suspected drug relationship), worsening hyperglycemia (grade 3, suspected drug relationship), dry heaves, nausea and vomiting (each grade 1, all unrelated to study drug), hypotension, and increased flushing (grades 2 and 1 respectively; both not related to study drug).

Weight loss occurred in 19 patients (42%) during the study, all cases of which were grades 1 or 2, with nine of the cases (20%) considered related to pasireotide. Maximum mean weight loss occurred within days 112–196 (weeks 16–28) of treatment with pasireotide, with a stabilization of effect after approximately week 28. There was no apparent relationship between weight loss and pasireotide dose.

Twenty-five patients were assessed for changes in blood glucose levels. Of these, 15 had baseline fasting blood glucose (FBG) levels $<100$ mg/dl. At the last assessment before study exit, four of the 15 patients continued to have FBG $<100$ mg/dl; five of the 15 patients had the highest post-baseline blood glucose level fall into the 100–126 mg/dl range and six had the highest post-baseline level fall into $>126$ mg/dl. Seven patients had baseline FBG levels between 100 and 126 mg/dl; of these patients, one remained in the 100–126 mg/dl range and six had the highest post-baseline level increased to $>126$ mg/dl. The three patients with baseline FBG $>126$ mg/dl remained in this category during treatment. For the majority of patients, the effect on FBG was transient as a result of
adjustments to the dose of pasireotide and appropriate antidiabetic management. Three of four patients who experienced an AE of worsening diabetic symptoms had a medical history of active diabetes mellitus, and three of the seven patients who experienced hyperglycemia had a history of active hyperglycemia at baseline. One additional patient who experienced an AE of hyperglycemia had a history of diabetes mellitus at baseline.

Discussion
Pasireotide 600–900 μg s.c. bid was effective in controlling the symptoms of diarrhea and flushing in 27% of patients with advanced NETs who were no longer responsive to octreotide LAR therapy. No clear dose–response relationship with regard to symptom control was observed. There was a minimal difference between the defined symptom reduction success rate of 30% and the observed 27% reduction of symptoms. Although the study did not meet its primary efficacy endpoint, potential activity of pasireotide in patients with advanced NETs refractory or resistant to octreotide LAR was observed and further studies are warranted. When observing HRQoL, the functional and physical well-being, symptom-specific scores, and total FACIT-D assessments showed some variability. Although there were no clear trends between patients who responded to pasireotide treatment and HRQoL, these results suggest that patients who responded to pasireotide improved their HRQoL slightly.

Recently, the antiproliferative effect of octreotide LAR was demonstrated in the randomized, double-blind, placebo-controlled PROMID study in patients with advanced, intestinal (midgut) NETs (Rinke et al. 2009), in which octreotide LAR 30 mg/28 days led to a significant increase in time to tumor progression compared with placebo (14.3 vs 6.0 months; \( P = 0.000072 \)), regardless of whether patients had a functioning or nonfunctioning tumor (Arnold et al. 2009, Rinke et al. 2009). In line with the antitumor effects of octreotide, pasireotide has been shown to have direct and indirect antitumor effects in vitro, including sst receptor-mediated apoptosis and inhibition of cell proliferation (Adams et al. 2004, Lattuada et al. 2007, Ono et al. 2007). In the current study, pasireotide treatment resulted in stable disease in more than half of the patients, which is a clinically relevant achievement in patients with functioning NETs refractory or resistant to octreotide LAR.

Pasireotide was absorbed rapidly, with \( C_{\text{max}} \) observed within 1 h post-dose in the majority of cases. Pasireotide exposure, assessed by \( C_{\text{min}}, C_{\text{max}}, \) and \( \text{AUC}_{0-6 \ h} \), appeared to be dose proportional; however, this effect could not be confirmed as formal statistical analysis was not conducted. An increased pasireotide concentration was observed at 6 h in the patient administered pasireotide 998 μg bid. As pasireotide has a high metabolic stability and does not

### Table 3 Pharmacokinetic parameters of pasireotide on day 28 following multiple bid dosing of pasireotide

<table>
<thead>
<tr>
<th>Dose (μg)</th>
<th>( n )</th>
<th>( t_{\text{max}} ) (h)</th>
<th>( C_{\text{max}} ) (ng/ml)</th>
<th>( C_{\text{min}} ) (ng/ml)</th>
<th>( \text{AUC}_{0-6 \ h} ) (ng/h per ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>150</td>
<td>1</td>
<td>0.50</td>
<td>4.7</td>
<td>1.4</td>
<td>15.0</td>
</tr>
<tr>
<td>450</td>
<td>4</td>
<td>0.79 (0.50–1.00)</td>
<td>15.2 ± 3.9</td>
<td>5.1 ± 1.6</td>
<td>58.4 ± 9.3</td>
</tr>
<tr>
<td>600</td>
<td>8</td>
<td>0.50 (0–0.50)</td>
<td>26.4 ± 12.2</td>
<td>9.9 ± 6.4</td>
<td>105 ± 53</td>
</tr>
<tr>
<td>750</td>
<td>8</td>
<td>0.75 (0.50–1.17)</td>
<td>31.6 ± 9.8</td>
<td>10.0 ± 4.0</td>
<td>128 ± 36</td>
</tr>
<tr>
<td>900</td>
<td>12</td>
<td>1.00 (0.50–3.00)</td>
<td>40.6 ± 17.8</td>
<td>13.5 ± 7.1</td>
<td>155 ± 66</td>
</tr>
<tr>
<td>998</td>
<td>1</td>
<td>0.52</td>
<td>51.9</td>
<td>15.2</td>
<td>231</td>
</tr>
<tr>
<td>1200</td>
<td>1</td>
<td>0.50</td>
<td>73.8</td>
<td>23.3</td>
<td>278</td>
</tr>
</tbody>
</table>

Data are described as median (range) for \( t_{\text{max}} \) and mean ± s.d. for all others. For groups with fewer than three patients, only median or mean values are reported. \( \text{AUC}_{0-6 \ h} \), area under the plasma concentration–time curve from 0 to 6 h; \( C_{\text{max}} \), maximum plasma concentration after a single dose; \( C_{\text{min}} \), minimum plasma concentration after a single dose; \( t_{\text{max}} \), time to reach the maximum concentration after a single dose.

### Table 4 Most frequently reported study drug-related adverse events for any dose group ≥5%\( ^a \) (\( n = 45 \))

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>( n ) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>12 (26.7)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>9 (20.0)</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>9 (20.0)</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>7 (15.6)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Flatulence</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4 (8.9)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Vertigo</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (6.7)</td>
</tr>
<tr>
<td>Headache</td>
<td>3 (6.7)</td>
</tr>
</tbody>
</table>

\( ^a \)Grade 3 adverse events of any frequency included diabetes mellitus \( (n = 1) \), hyperglycemia \( (n = 3) \), abdominal pain \( (n = 2) \), vomiting \( (n = 1) \), general physical health deterioration \( (n = 1) \), procedural nausea \( (n = 1) \), and blood amylase increase \( (n = 1) \). One patient experienced a grade 4 increase in lipase levels.
interact with CYP450 enzymes or P-glycoprotein, a potential drug–drug interaction is unlikely, especially as the increase was not correlated with the presence of a concomitant medication. As the increased pasireotide concentration was observed at one time point only, the finding can be attributed to bioanalytical assay variability. In the patients who responded to pasireotide treatment, the median effective plasma concentration of pasireotide was observed at around 10 ng/ml, which was based on the observed mean value of $C_{\text{min}}$ at pasireotide 600, 750, and 900 µg bid. At these three dose levels, clinical response (symptom control) to pasireotide was observed with similar frequency.

There is a well-established safety profile for sst analogs, attributable to their clinical use in the treatment for NETs for over two decades. The most frequent AEs are abdominal pain with cramps, constipation, diarrhea, steatorrhea, injection-site irritation, nausea, and vomiting (Modlin et al. 2010). In the current study, a similar tolerability profile was observed, with most AEs being of mild or moderate severity. Some patients required an adjustment to the dose of pasireotide, and additional therapy was prescribed to treat some of the AEs. Treatment with pasireotide at all doses examined in this study was associated with hyperglycemia. Hyperglycemia has previously been observed in up to 27% of patients administered long-acting sst analogs (Ipsen Ltd. Somatuline depot (lanreotide) injection prescribing information 2007, available at: www.somatulinedepot.com/hcp/full-prescribing-information.asp; Novartis Sandostatin LAR Depot (octreotide acetate for injectable suspension) prescribing information 2010, available at: www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdf). In general, few studies report details of weight change in patients with NETs.

The response rate seen in this study may be attributed to the fact that difficult-to-treat patients were evaluated. Further studies may identify subgroups with greater rates of tumor response. Pasireotide may potentially be more effective in early treatment of patients with well-differentiated tumors. Additionally, although the majority of patients appeared to experience stable disease during treatment with pasireotide, interpretation of this finding is complex. Randomized studies, such as the PROMID trial that confirmed the antitumor effect of octreotide LAR (Rinke et al. 2009), are required to confirm any such effect with pasireotide. A phase III study evaluating pasireotide LAR vs octreotide LAR is ongoing in patients with metastatic carcinoid NETs whose disease-related symptoms are inadequately controlled by sst analogs.

In conclusion, clinical responses to pasireotide treatment were seen at doses of 600 µg bid and higher, and pasireotide controlled the symptoms of diarrhea and flushing in 27% of patients with advanced NETs who were refractory or resistant to the standard therapy, octreotide LAR. HRQoL was maintained with pasireotide therapy. Pasireotide treatment was generally well tolerated, with adverse gastrointestinal events being the most common. These results demonstrate that pasireotide is a potential treatment option for patients with symptoms of carcinoid syndrome who are resistant or refractory to octreotide LAR therapy. A phase III study comparing pasireotide LAR with octreotide LAR in patients with advanced NETs is ongoing.

Declaration of interest

L K Kvols has consulted, received research funding and honoraria from Novartis, and has also received research funding from Pfizer, Lexicon Pharmaceutical, and the Southwest Oncology Group (SWOG). K E Oberg has received honoraria from Novartis, Ipsen, and Pfizer and serves on advisory boards for Novartis, Ipsen, and Pfizer. T M O’Dorisio has nothing to disclose. W W de Herder has consulted for Novartis Pharmaceuticals. R Arnold has received research funding and honoraria from Novartis. L Anthony has served on advisory boards for Novartis.
B. Wiedenmann has received consulting and lecture fees and payment for educational presentations from Pfizer. P. Mohideen, K. Hu, Y. Zhang, and G. Hughes are employees of Novartis.

**Funding**

Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. This study was funded by Novartis Pharma AG.

**Author contribution statement**

L. K. Kvols, K. E. Oberg, T. M. O’Dorisio, W. W. de Herder, R. Arnold, L. Anthony, and B. Wiedenmann contributed to the design and conduct of the study, as well as acquisition and interpretation of data. P. Mohideen, K. Hu, Y. Zhang, and G. Hughes contributed to the design of the study and interpretation of data. G. Hughes performed the statistical analysis of data. All authors critically reviewed and approved the final manuscript.

**Acknowledgements**

The authors acknowledge the following investigators for their participation in this study: Anthony Heaney and Philippe Ruszniewski. The authors thank Keri Wellington and Helene Darmofal for medical editorial assistance with this manuscript.

**References**


Received in final form 12 June 2012
Accepted 27 June 2012
Made available online as an Accepted Preprint 17 July 2012